Skip to main content

Table 1 Baseline characteristics of trial population

From: Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial

 

Liraglutide (n = 23)

Placebo (n = 26)

Demographics

 Age in years  (SD)

60 (6)

59 (7)

 Male

14 (61%)

15 (58%)

 Diabetes duration in years (SD)

11 (6)

11 (7)

 Diabetes complications

  Retinopathy, n

4 (17%)

2 (8%)

  Nephropathy, n

2 (9%)

11 (42%)

  Neuropathy

10 (44%)

7 (27%)

  Macrovasculara

2 (9%)

0 (0%)

Clinical parameters

 Weight in kg (SD)

98 (14)

94 (13)

 Body-mass index in kg/m2 (SD)

32.6 (4.4)

31.6 (3.4)

 Systolic blood pressure in mmHg (SD)

141 (14)

141 (15)

 Diastolic blood pressure in mmHg (SD)

86 (6)

87 (11)

 Glycated haemoglobin A1c in % (SD)

8.4 (1.1)

8.2 (1.0)

 Glycated haemoglobin A1c in mmol/mol (SD)

67 (12)

65 (10)

 Serum creatinine in μmol/L (SD)

73 (19)

68 (17)

 Urinary albumin/creatinine ratio in mmol/μg (SD)

1.0 (1.3)

5.0 (8.9)

 Triglycerides in mmol/L (SD)

2.2 (1.5)

2.1 (1.1)

 Total cholesterol in mmol/L (SD)

4.8 (1.0)

4.8 (1.0)

 HDL-c in  mmol/L (SD)

1.2 (0.2)

1.3 (0.4)

 LDL-c in mmol/L (SD)

2.6 (0.9)

2.5 (0.9)

Smoking history

 Never smoked, n

10 (44%)

8 (31%)

 Current smoker, n

4 (17%)

5 (19%)

 Ex-smoker, n

9 (39%)

13 (50%)

Concomitant drug use

 Metformin dose in g/day (SD)

2.1 (0.7)

2.0 (0.5)

 Sulfonylurea, n

6 (26%)

8 (31%)

 Insulin, n

15 (65%)

17 (65%)

 Anti-lipidaemic, n

21 (91%)

19 (73%)

 Anti-hypertensive, n

18 (78%)

20 (77%)

LV diastolic function

 E in mL/s (SD)

331 (99)

325 (96)

 A in mL/s (SD)

367 (79)

371 (70)

 E/A ratio (SD)

0.95 (0.44)

0.90 (0.31)

 Edec in mL/s2 × 10−3 (SD)

2.9 (0.9)

2.6 (1.2)

 Ea in cm/s (SD)

6.0 (1.6)

6.0 (1.8)

 E/Ea (SD)

7.3 (2.9)

7.9 (2.3)

LV systolic function

 Stroke volume in mL (SD)

81 (16)

76 (18)

 Ejection fraction in % (SD)

55 (5.8)

55 (4.5)

 Cardiac output in L/min (SD)

5.4 (0.9)

5.5 (1.0)

 Cardiac index in L/min/m2 (SD)

2.5 (0.3)

2.6 (0.4)

 Peak ejection rate in mL/s (SD)

442 (96)

415 (92)

  1. E early transmitral peak flow rate, A late transmitral peak flow rate, Edec peak deceleration of transmitral early peak flow, Ea early peak mitral annular septal tissue velocity
  2. aMacrovascular complications were cerebrovascular or peripheral artery disease and not cardiovascular